Anti-Protein C Inhibitor Antibody, Non-Fucosylated (PC19G8) (CAT#: BioBet-1277ZP) Datasheet

SERPINA5

serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5

The protein encoded by this gene is a member of the serpin family of proteins, a group of proteins that inhibit serine proteases. This gene is one in a cluster of serpin genes located on the q arm of chromosome 14. This family member is a glycoprotein that can inhibit several serine proteases, including protein C and various plasminogen activators and kallikreins, and it thus plays diverse roles in hemostasis and thrombosis in multiple organs.

SERPINA5; serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5; PCI; PAI3; PAI-3; PCI-B; PROCI; PLANH3; plasma serine protease inhibitor; protein C inhibitor; plasminogen activator inhibitor-3; acrosomal serine protease inhibitor; plasminogen activator inhibitor III; serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5

Extracellular region or secreted

Diseases associated with SERPINA5 include Thrombosis and Epilepsy, Idiopathic Generalized 13.

Its related pathways are Formation of Fibrin Clot (Clotting Cascade) and Response to elevated platelet cytosolic Ca2+.

Heparin-dependent serine protease inhibitors act on body fluids and secretions. The serine protease is inactivated by irreversibly binding to the serine activation site of the serine protease. Participate in the regulation of intravascular and extravascular proteolytic activity. Hemostasis in the plasma. By inhibiting anticoagulant activated protein C factor and thrombin/thrombomodulin complex to produce activated protein C factor, as a procoagulant and pro-inflammatory factor. As an anticoagulant factor, it inhibits coagulation factors such as prothrombin, factor XI, factor Xa, plasma kininase and plasmin such as tissue and urine plasminogen activator. In seminal plasma, it inactivates several serine proteases related to the reproductive system. Inhibit serpin acrosin; indirectly protect the components of the male reproductive tract from being destroyed by excessive release of acrosin. Inhibit tissue and urine-type plasminogen activator, prostate specific antigen and kininase activity; control sperm motility and fertilization. Inhibit the degradation of SEMG1 and SEMG2 catalyzed by activated protein c; regulate the degradation of sperm lecithin during the transfer of sperm from the male reproductive tract to the female reproductive tract. In urine, inhibit the activity of urinary plasminogen activator and kininase. The inactivated membrane anchors the activity of serine proteases, such as MPRSS7 and TMPRSS11E. Inhibit the invasion and metastasis of urinary plasminogen activator-dependent tumor cells. It may also play a non-inhibitory effect in seminal plasma and urine, acting as a hydrophobic hormone carrier and binding retinoic acid.

N- and O-glycosylated. N-glycosylation consists of a mixture of sialylated bi- (including sialyl-Lewis X epitopes), tri- and tetra-antennary complex-type chains; affects the maximal heparin- and thrombomodulin-enhanced rates of thrombin inhibition. O-glycosylated with core 1 or possibly core 8 glycans. Further modified with 2 sialic acid residues. Proteolytically cleaved. Inhibition of proteases is accompanied by formation of a stable enzyme-inhibitor complex and by degradation of the serpin to lower molecular weight derivatives. Proteolytically cleaved at the N-terminus; inhibits slightly the heparin- and thrombomodulin-enhanced rates of thrombin inhibition.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

PC19G8

Humanized

Human

The anti-PCI antibody having Protein C inhibitor (PCI) can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

Thrombosis; Sepsis

Thrombosis; Sepsis